stockportfolio.pro
Stocks / ABT vs DHR
ABT vs DHR
Abbott Laboratories and Danaher Corporation side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
ABT is the larger company ($154.2B vs $125.8B). On the fundamentals, ABT grows revenue faster (5.1% vs 2.0%); ABT earns a higher net margin (14.7% vs 14.7%); ABT has the stronger return on equity (12.5% vs 6.9%). Full numbers below — the stronger figure on each row is in green.
| Abbott Laboratories (ABT) | Danaher Corporation (DHR) | |
|---|---|---|
| Market cap | $154.2B | $125.8B |
| Revenue (latest FY) | $44.33B | $24.57B |
| Net income (latest FY) | $6.52B | $3.61B |
| Revenue growth (5y CAGR) | 5.1% | 2.0% |
| Net margin | 14.7% | 14.7% |
| Return on equity | 12.5% | 6.9% |
| P/E ratio | 24.8 | 34.4 |
| Dividend yield | — | — |
| Profitable years (of last 10) | 10 | 10 |
| Positive free cash flow | Yes | Yes |
Compare with another company:
See the full ABT vs DHR breakdown
Both companies across 19 years of income statement, balance sheet and cash flow — with ratios, health checks and Ask, the SEC-grounded research assistant. Free, no account needed.
Open ABT's full financials → Open DHR's full financials →Frequently asked questions
Which is bigger, ABT or DHR?
Abbott Laboratories is larger by market capitalization — $154.2B versus $125.8B.
Which grows faster, ABT or DHR?
Over the last five fiscal years, Abbott Laboratories grew revenue faster — 5.1%/yr versus 2.0%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.